TY - JOUR
T1 - Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment
AU - Niaura, Raymond
AU - Spring, Bonnie
AU - Borrelli, Belinda
AU - Hedeker, Donald
AU - Goldstein, Michael G.
AU - Keuthen, Nancy
AU - Depue, Judy
AU - Kristeller, Jean
AU - Ockene, Judy
AU - Prochazka, Allan
AU - Chiles, John A.
AU - Abrams, David B.
N1 - CA84719, NCI NIH HHS, United StatesHL32318, NHLBI NIH HHS, United StatesP50 CA084719, NCI NIH HHS, United StatesR01 HL032318, NHLBI NIH HHS, United States
PY - 2002
Y1 - 2002
N2 - The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
AB - The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
U2 - 10.1037//0022-006X.70.4.887
DO - 10.1037//0022-006X.70.4.887
M3 - Article
C2 - 12182272
SN - 1939-2117
VL - 70
SP - 887
EP - 896
JO - Journal of Consulting and Clinical Psychology
JF - Journal of Consulting and Clinical Psychology
IS - 4
ER -